BPC-157 (20 mg) is a synthetic 15-amino-acid peptide originally identified as a stable fragment from a gastric juice protein. This BPC-157 peptide is linear and proline-rich. Supplied as a lyophilized powder in a single research vial, the product is typically verified for identity and purity by HPLC and mass spectrometry.
BPC-157 has been studied for its effects on tissue-repair-related endpoints, vascular responses, and inflammation in laboratory models. Current work focuses on preclinical and exploratory research applications, not on validated clinical use.
BPC-157 (20 mg) Key Features & Specs
- Subcategory: Healing & Regenerative Peptides
- Strength: 20 mg
- CAS: 137525-51-0
- Chemical Formula: C₆₂H₉₈N₁₆O₂₂
- Molecular Weight: 5 g/mol
- Peptide Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- Synonyms: BPC157, Bepecin
The BPC-157 research peptide should only be used for controlled laboratory investigation.
BPC-157 (20 mg) Research Uses
Researchers use Body Protection Compound 157 (BPC-157) to investigate processes associated with tissue-protection-related and tissue-repair-related endpoints. Common research areas include:
- Musculoskeletal repair (tendons, ligaments, muscle, bone)
- Gastrointestinal mucosal protection and ulcer models
- Vascular tone and angiogenesis studies
- Neuroprotection and models of nerve injury
- Inflammation and oxidative-stress modulation
BPC-157 peptide is primarily preclinical, used in cell culture and animal models. Studies typically measure histology, biomechanical readouts, vascular responses, and biochemical markers—rather than clinical effectiveness.
BPC-157 (20 mg) Insights & Observed Findings
Key, model-specific findings from the literature include:
- Animal Tendon and Muscle Models: Low microgram-to-nanogram-per-kilogram dosing (route and schedule vary by study) has been associated with changes in tissue organization, vascularization, and biomechanical readouts compared with controls.
- Vascular Studies: BPC-157 has been observed to modulate vasomotor tone in isolated vessels and to interact with nitric oxide–related signaling in a concentration-dependent manner.
- Gastrointestinal Models: Intragastric or parenteral dosing in rodents has been associated with changes in mucosal damage and tissue-repair-related outcomes across various injury models.
- Cellular Assays: Nanomolar concentrations have been used to study endothelial migration, fibrillar actin assembly, and focal adhesion signaling in vitro.
- Safety Landscape: The bulk of safety-related data currently comes from preclinical reports. A small number of early human safety/pharmacokinetic studies and pilot reports have emerged; these are preliminary and require further confirmation.
All reported outcomes are model- and protocol-specific. Investigators should consult original studies for exact dosing, timing, routes, and assay conditions before designing experiments.
BPC-157 (20 mg) Handling & Storage
- Store the sealed lyophilized vial at –20 °C or below, protected from light and moisture.
- Allow the unopened vial to reach room temperature before opening to reduce condensation.
- Reconstitute using sterile, particle-free aqueous buffer and aseptic technique appropriate to your laboratory protocol.
- Reconstituted solutions intended for experimental use are commonly kept refrigerated (2–8 °C) and protected from light.
- Follow institutional biosafety, handling, and waste-disposal procedures for all experimental work.
Compliance Notice: This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.
References
- Siric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology. 2006;14(5-6):214-221. doi:10.1007/s10787-006-1531-7
- Sikiric P. The pharmacological properties of the novel peptide BPC 157 (PL-10). Inflammopharmacology. 1999;7(1):1-14. doi:10.1007/s10787-999-0022-z
- Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. doi:10.1016/j.yrtph.2020.104665
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2010;110(3):774-780. doi:10.1152/japplphysiol.00945.2010
- Sikiric P, Blagaic AB, Strbe S, et al. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals. 2024;17(4):461. doi:10.3390/ph17040461
- McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. doi:10.1007/s12178-025-09990-7